Isopropyl Unoprostone

Isopropyl Unoprostone is synthetic analogue of dinoprost (prostaglandin F-2a) that is used topically as the isopropyl ester for the treatment of glaucoma and ocular hypertension.

Isopropyl Unoprostone is primarily indicated in conditions like Glaucoma, Ocular hypertension.

Isopropyl Unoprostone is contraindicated in conditions like Intraocular hypertension, Hypersensitivity to any component of product.

The symptomatic adverse reactions produced by Isopropyl Unoprostone are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Palpitation, Nausea and vomiting, Dermatitis, Blurring of vision, Numbness, Dryness, Conjunctival hyperemia, Corneal changes, Keratitis, Ocular irritation and pain.

Concerns related to adverse effects: • Ocular pigmentation: May cause permanent change in eye color (increases the amount of brown pigment in the iris, may not be noticeable for months to years); long-term consequences and potential injury to eye are not known. May also cause pigment changes to periorbital tissues and eyelashes during use; reversible upon discontinuation in most patients. • Infection: Bacterial keratitis, caused by inadvertent contamination of multiple-dose ophthalmic solutions, has been reported. Minimize contamination by not touching the eyelids or surrounding areas with the dropper tip; keep bottle tightly closed when not in use. Disease-related concerns: • Ocular disease: Use with caution in patients with intraocular inflammation (eg, uveitis); may exacerbate intraocular inflammatory conditions. May cause macular edema, including cystoid macular edema; use cautiously in aphakic patients, pseudophakic patients with torn posterior lens capsules, or in patients at risk for macular edema. Special populations: • Contact lens wearers: Contains benzalkonium chloride which may be adsorbed by contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting. Dosage form specific issues: • Contains benzalkonium chloride 0.015% as a preservative.

Concerns related to adverse effects: • Ocular pigmentation: May cause permanent change in eye color (increases the amount of brown pigment in the iris, may not be noticeable for months to years); long-term consequences and potential injury to eye are not known. May also cause pigment changes to periorbital tissues and eyelashes during use; reversible upon discontinuation in most patients. • Infection: Bacterial keratitis, caused by inadvertent contamination of multiple-dose ophthalmic solutions, has been reported. Minimize contamination by not touching the eyelids or surrounding areas with the dropper tip; keep bottle tightly closed when not in use. Disease-related concerns: • Ocular disease: Use with caution in patients with intraocular inflammation (eg, uveitis); may exacerbate intraocular inflammatory conditions. May cause macular edema, including cystoid macular edema; use cautiously in aphakic patients, pseudophakic patients with torn posterior lens capsules, or in patients at risk for macular edema. Special populations: • Contact lens wearers: Contains benzalkonium chloride which may be adsorbed by contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting. Dosage form specific issues: • Contains benzalkonium chloride 0.015% as a preservative.

0.06 mg (0.06 (0.06)) 12 hourly Ophthalmic — - 0.12 % (0.12 (0.12)) 12 hourly Ophthalmic — drops. Scraped Dose — Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product Solution, Ophthalmic, as isopropyl ester: Rescula: 0.15% (5 mL [DSC]) [contains benzalkonium chloride, edetate disodium, polysorbate 80]

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). Monitor therapy Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents (Ophthalmic) may enhance the therapeutic effect of Prostaglandins (Ophthalmic). Monitor therapy

Store Below 15°C.